+44 20 8123 2220
info@marketpublishers.com

Peripheral Arterial Disease (Pad)/ Pulmonary Vascular Disease (Pvd) - Market Access, Reimbursement Outlook, Competitive Landscape, Epidemiology and Forecast Report - 2015 To 2030

https://marketpublishers.com/r/P146668A8D9EN.html
Date: March 2018
Pages: 217
Price: US$ 6,550.00 (Single User License)
ID: P146668A8D9EN

Abstracts

Thelansis Knowledge Partners 'Peripheral Arterial Disease (PAD)/ Pulmonary Vascular Disease (PVD)' - Market Access, Reimbursement Outlook, Competitive Landscapet, Epidemiology and Forecast Report – 2015 to 2030' report comprises of the Disease overview, classifications, stages or severity level, pathogenesis, identified and emerging biomarkers, pipeline assessment, competitive landscape, KOLs perspective, Market access - Country Specific Regulatory scenario
s, Patent landscape, reimbursement scenario; Public, Private, Medicare, Medicaid, Government, Private, Co-payment, Out of pocket, Epidemiology; Incidence, Prevalence, Mortality, and current therapy market share, Order of entry, patient share, Market uptake, Peak patient share, Disease burden, Annual cost of therapy, market forecast for USA, Germany, France, Italy, Spain, UK, Japan and China 2015 to 2030

Geographic Coverage

United States

EU5 (Germany, France, Italy, Spain and the United Kingdom)

Japan

China

+44 20 8123 2220
info@marketpublishers.com

Market estimation: 2015 – 2030

Report brief:

Epidemiology

This section provide the insights about historical and current patient pool (Incidence, Prevalence and mortality) and forecasted trend for 8 major markets (US, Germany, France, Italy, Spain, UK, Japan and China). The epidemiology research is one the key element of the report driven by meta-analysis, Systemic literature review and insights from KOL's

Treatment Algorithm

The comprehensive details on country specific treatment and disease management for the patients in the US, Europe, Japan, and China. Future treatment paradigm and KOL's perspective (HCP's, Payers and Researcher) are the key strength of the report

Competitive Landscapet

A thorough analysis of reported revenue, patient share and marketed trend for approved therapies however for pipeline assets we consider Phase I, Phase II and Phase III including their major milestones, study result, interim result, safety & efficacy data, key drivers, mechanism of action designation (Fast Track, Breakthrough Therapy, Accelerated Approval, Priority Review) geography level prioritization, asset level profile and probable launch date estimation

Market Outlook & Market Forecast

Historic, current and forecasted market trend (High, Base case, Low) of the market by analyzing the impact of current therapies on the market, unmet needs, drivers and barriers and demand of better diagnosis of biomarkers. Key patient segment and market based on type, severity and stages of the disease. Disease burden, compliance rate, annual cost of therapy, reimbursement scenario, Patient share, Patient access

Market uptake and benchmarking

The market penetration for pipeline assets being derived on the basis of benchmarking the sales of launched assets specifically targeting the patient segment or overall

+44 20 8123 2220
info@marketpublishers.com

indication or therapy area or country or region specific. Order of entry benchmark works as a critical element for defining the uptake curve for the pipeline assets. Many drug utilization study are being benchmarked to arrive at the current patient share for marketed therapies as well as off-label products. Market events are the major key factors which applied to the forecast model to optimize the year on year revenue estimation

Regulatory scenario

Country specific healthcare structure, regulatory bodies, HTA bodies, approval process for diagnostic and therapies, and work flow

Patent landscape

Country specific patent filings for approved therapies as well as pipeline assets, formulation patent, process patent (FDA, EMA, EPO, Orange book, JPO; Japan Patent Office) and fillings

Reimbursement Scenario

Country specific reimbursement Scenario; Public, Private, Medicare, Medicaid, Government, Private, Co-payment, Out of pocket

Key Report highlights

- 4 years of historical epidemiology data Epidemiology; Incidence, Prevalence, Mortality
- 11 years of epidemiology and market projections
- Incidence/ Prevalence patient population
- Mortality, survival and diagnosed patient pool
- Treated patient pool
- Treatment guidelines
- Competitive landscape (Marketed therapies, Off-label therapies, Pipeline

+44 20 8123 2220
info@marketpublishers.com

assessment, Phase – I, II, III)

Patient share

Country specific revenue share and trend

Market Opportunities assessment

Key market and product event analysis

Disease burden and annual cost of therapy

Regulatory scenario

Reimbursement Scenario

Patent landscape

HCP’s/ KOL’s perspective

Payer’s perspective

Analyst commentary Rheacell Gmbh & Co. Kg, Inova Health Care Services, Merck Sharp & Dohme Corp., Boston Scientific Corporation, Humacyte, Inc., Atlantic Research Group, Shenzhen Salubris Pharmaceuticals Co., Ltd., Avazzia, Inc, Brian Lepow, Dpm, Gilead Sciences, The Medicines Company, Pharmicell Co., Ltd., Covis Pharma S.Ã .R.L., Fluoropharma, Inc., Eicos Sciences, Inc., Dexa Medica Group, Cardiovascular Biotherapeutics, Inc., Bayer, Janssen Research & Development, Llc, Polysan Scientific & Technological Pharmaceutical Company, Celularity Incorporated, Juventas Therapeutics, Inc., Humacyte, Inc., Proteon Therapeutics, Novartis, Sonacare Medical, Takeda, Yuhan Corporation, Biogencell Ltd., Spectranetics Corporation, Mercator Medsystems, Inc., Biotronik (Beijing) Medical Device Ltd., Lee'S Pharmaceutical Limited, Alucent Medical, Inc., Northwestern University, Helixmith Co., Ltd., Merck Sharp & Dohme Corp., Reven Pharmaceuticals, Inc., Helixmith Co., Ltd., M.A. Med Alliance S.A., Merck Sharp & Dohme Corp., Boston Scientific Corporation, Bracco International B.V.

Market Publishers
+44 20 8123 2220
info@marketpublishers.com

Contents

+44 20 8123 2220
info@marketpublishers.com

+44 20 8123 2220
info@marketpublishers.com

5. COMPETITIVE LANDSCAPE

2. Trials
3. Approval Timeline
4. Expected Product Positioning
5. Market Forecast (Till 2030)
6. Attribute analysis
4. Pre-clinical Therapies
1. Asset - Company
1. Current Status
2. Pre-clinical Trials
3. Estimated Timelines
2. Asset - Company
1. Current Status
2. Pre-clinical Trials
3. Estimated Timelines
3. Asset - Company
1. Current Status
2. Pre-clinical Trials
3. Estimated Timelines
5. Inactive Therapies
1. Asset - Company
1. Current Status
2. Reasons for Inactivation
2. Asset - Company
1. Current Status
2. Reasons for Inactivation
3. Asset - Company
1. Current Status
2. Reasons for Inactivation

6. REGULATORY FRAMEWORK SCENARIO

1. Regulatory Framework in US
1. Approval Framework(s)
2. Clinical Trial Guidance
3. Macro Policies (if any)
4. Expectations on Future Pricing and Reimbursement Outlook
2. Regulatory Framework in UK
1. Approval Framework(s)
2. Clinical Trial Guidance

+44 20 8123 2220
info@marketpublishers.com

5. Attrition analysis
    1. Failed Trials, Reasons and Business Impact
    2. Terminated Trials, Reasons and Business Impact
    3. Withdrawn Trials, Reasons and Business Impact
6. Trial enrollment scenario and challenges
7. Clinical Trial Guidance (across geographies)

8. MARKET ACCESS

1. Market access-payers perspective,
2. Country Specific Regulatory scenarios,
3. Patent landscape,
4. reimbursement scenario; Public, Private,
5. Medicare, Medicaid,
6. Government, Private, Co-payment, Out of pocket

9. THELANSIS' COMMENTARY

1. Key Unmet needs in Indication-Disease
2. Possible Best-case Clinical Trial Strategies
3. Possible Best-case Market positioning strategies
4. Possible Best-case Market Access Strategies
5. Overall View on Indication-Disease Market in Dollar Value

10. REPORT METHODOLOGY

1. Secondary research
2. Primary research
3. Data collation
4. Insight Generation

11. ABOUT THELANSIS

1. Our Capabilities
2. Our Services
3. Our Contacts
4. Disclaimer

+44 20 8123 2220
info@marketpublishers.com

I would like to order

Product name: Peripheral Arterial Disease (Pad)/ Pulmonary Vascular Disease (Pvd) - Market Access, Reimbursement Outlook, Competitive Landscape, Epidemiology and Forecast Report - 2015 To 2030

Product link: https://marketpublishers.com/r/P146668A8D9EN.html

Price: US$ 6,550.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

info@marketpublishers.com

Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page https://marketpublishers.com/r/P146668A8D9EN.html

To pay by Wire Transfer, please, fill in your contact details in the form below:

First name:

Last name:

Email:

Company:

Address:

City:

Zip code:

Country:

Tel:

Fax:

Your message:

**All fields are required

Custumer signature _______________________________

Please, note that by ordering from marketpublishers.com you are agreeing to our Terms & Conditions at https://marketpublishers.com/docs/terms.html

To place an order via fax simply print this form, fill in the information below

+44 20 8123 2220
info@marketpublishers.com

and fax the completed form to +44 20 7900 3970